Table 2.
Clinical Outcomes for Study Eyes After Intravitreal Injection of Bevacizumab
| Clinical outcome | Study eyes (n=17) |
|---|---|
| Number of IVIA (mean±SD) | 1.4±0.5 |
| Time of NVD regression (weeks) (mean±SD) | 10.8±3.4 |
| VCUT without vitrectomy (weeks) (mean±SD) | 8.5±2.2 |
| Eyes underwent vitrectomy during follow-up [n (%)] | 3 (18) |
| Indication for vitrectomy [n (%)] | |
| Dense VH | 2 (66.7) |
| Focal TRD | 1 (33.3) |
| Baseline BCVA (logMAR) | 1.03±0.64 |
| 6 months BCVA (logMAR) | 0.48±0.43 |
| Difference between baseline and 6 months BCVAa (logMAR) | 0.56±0.55 |
a
Statistical analysis of the difference between baseline and 6 months BCVA was performed using the Wilcoxon t test: P<0.01 (P<0.05 was considered statistically significant).
IVIA, intravitreal injection of Avastin; NVD, neovascularization on the disc; VCUT, vitreous clear-up time; TRD, tractional retinal detachment; VH, vitreous hemorrhage; BCVA, best-corrected visual acuity; logMAR, logarithm of the minimum angle resolution.